Gland Pharma Limited (NSE:GLAND)
India
· Delayed Price · Currency is INR | Market Cap | 267.80B |
| Revenue (ttm) | 56.17B |
| Net Income (ttm) | 6.99B |
| Shares Out | 164.76M |
| EPS (ttm) | 42.40 |
| PE Ratio | 38.33 |
| Forward PE | 28.43 |
| Dividend | 18.00 (1.13%) |
| Ex-Dividend Date | Aug 14, 2025 |
| Volume | 112,378 |
| Average Volume | 163,282 |
| Open | 1,605.00 |
| Previous Close | 1,588.90 |
| Day's Range | 1,588.40 - 1,638.00 |
| 52-Week Range | 1,277.80 - 2,220.95 |
| Beta | 0.27 |
| RSI | 65.75 |
| Earnings Date | May 20, 2025 |
About Gland Pharma
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood ... [Read more]
Financial Performance
In 2024, Gland Pharma's revenue was 56.17 billion, a decrease of -0.85% compared to the previous year's 56.65 billion. Earnings were 6.99 billion, a decrease of -9.57%.
Financial StatementsNews
Gland Pharma shares rise over 3% following Q4 Results
Shares of Gland Pharma Ltd surged 3.34% to ₹1,548.30 on Wednesday, following the company’s Q4 FY25 results. Despite a decline in profit and sales, investor sentiment remained upbeat, possibly buoyed b...
Gland Pharma share price: Nomura sees 4% upside, maintains neutral on soft Q4 and cautious outlook
Nomura has maintained its neutral stance on Gland Pharma with a target price of ₹1,570, reflecting a modest upside of 4% from the current market price of ₹1,503.90. The cautious view follows a mixed Q...
Brokerage radar: Hindalco, BEL, Dixon, Zydus, Gland Pharma in focus after Q4; target prices revised
Top brokerages including CLSA, Morgan Stanley, Nomura and Nuvama have released fresh commentary on several Indian stocks following their Q4FY25 results. The reports highlight key upgrades, revised tar...
Top stocks to watch today, May 21: NHPC, Dixon Technologies, Whirlpool India, IRCON, Gland Pharma and more
Indian stock markets closed lower on May 20, 2025, with the BSE Sensex falling 872.93 points (1.06%) to end at 81,186.44, while the NSE Nifty50 dropped 261.55 points (1.05%) to finish at 24,683.90. Ah...
Gland Pharma Q4 Results: Revenue falls 7.3% YoY to Rs 1,424.9 crore, Net Profit falls 3.1% YoY
Gland Pharma Limited reported a sharp decline in its consolidated net profit for the fourth quarter ended March 31, 2025 (Q4 FY25). The company posted a net profit of ₹186.5 crore, down 3.1% from ₹192...
Q4 Results Today, May 20: NHPC, Dixon Technologies, Gland Pharma, Zydus Lifesciences, Hindalco among companies reporting earnings
A total of 146 companies are scheduled to release their financial results for the January-March quarter on Tuesday, May 20. These earnings reports will provide insight into the performance of these fi...
Indian pharma stocks tumble as Trump signals tariffs on drug imports
Indian pharmaceutical stocks experienced a downturn following Donald Trump's renewed threat to impose tariffs on pharmaceutical imports. The Nifty Pharma index fell by 1.7%, with major companies like ...
Gland Pharma shares drop over 5% as Trump hints at pharma tariffs
Shares of Gland Pharma Ltd fell 5.29% to ₹1,477.00 on Friday, slipping ₹82.50 from the previous close of ₹1,559.50, following renewed concerns around potential U.S. tariffs on pharmaceutical imports. ...
Gland Pharma secures USFDA approval for Acetaminophen Injection
Gland Pharma Limited, a leading generic injectable pharmaceutical company, has received approval from the U.S. Food and Drug Administration (USFDA) for its Acetaminophen Injection (10 mg/mL, 500mg/50m...
Gland Pharma shares surge nearly 10% as Trump spares Indian pharma sector from 26% reciprocal tariff
Shares of Gland Pharma rallied sharply on April 3, jumping 9.76% to ₹1,685 after the U.S. government clarified that pharmaceutical imports would be excluded from the new 26% reciprocal tariffs unveile...
Pharma and hospital stocks in focus today: Alembic Pharma, Gland Pharma, Apollo Hospital, Fortis Healthcare, Dr Reddy’s [March 24, 2025]
Pharma and hospital-related stocks are seeing heightened investor interest today, March 24, 2025, following key developments. Alembic Pharma announced the successful completion of a US FDA inspection ...
Gland Pharma receives three form 483 observations after US FDA inspection at JNPC facility
Gland Pharma Limited announced that the United States Food and Drug Administration (US FDA) has concluded its pre-approval inspection (PAI) at the company’s JNPC facility in Visakhapatnam. The inspect...
Gland Pharma Ltd (NSE:GLAND) Q3 2025 Earnings Call Highlights: Strong Margins Amid Revenue ...
Gland Pharma Ltd (NSE:GLAND) Q3 2025 Earnings Call Highlights: Strong Margins Amid Revenue Challenges
Q3 2025 Gland Pharma Ltd Earnings Call Transcript
Q3 2025 Gland Pharma Ltd Earnings Call Transcript
Gland Pharma shares drop 2% as revenue dips 10% YoY in Q3
Gland Pharma’s stock saw a drop of over 2% in morning trade after the company released its Q3 FY25 results, reporting a 6.7% year-on-year (YoY) rise in net profit. For the third quarter ending Decembe...
Top stocks to watch in trade today, February 4: Garden Reach, NLC India, KEC International, Power Grid, Gland Pharma and more
The Indian stock markets are expected to open on a positive note, as indicated by the GIFT Nifty. On Monday, the key benchmark indices ended in the red. The BSE Sensex closed at 77,186.74, down by 319...
Jefferies cuts target price for Gland Pharma to Rs 1,350 after Q3 results
Jefferies has downgraded its target price for Gland Pharma to Rs 1350 while maintaining an ‘Underperform’ rating, following another disappointing quarter. The company reported weak revenue growth in i...
Gland Pharma Q3 Results: Net profit rises 11.8% YoY to Rs 204.62 crore, Revenue at Rs 1384.05 crore
Gland Pharma Limited reported its Q3 financial results for the quarter ended December 31, 2024, showcasing stable growth despite minor sequential revenue contractions. The company reported a net profi...
Stocks hitting 52-week low today, January 28: GAIL, Gland Pharma, BHEL, RITES, Graphite India, SKF India and more
The Indian equity markets rebounded on January 28, ending a two-day losing streak as benchmark indices showed positive momentum. While the Nifty 50 index rose by 128.1 points to close at 22,957.25, an...
52 week low stocks today on January 24: Axis Bank, Sterling, Gland Pharma, Rajesh Exports, Cyient and more
The Indian stock market opened on a positive note on Friday, with both major indices, the Sensex and Nifty, rising following a strong global market trend. The 30-share BSE benchmark Sensex surged by 2...
Top stocks to watch in trade today: Wipro, Tech Mahindra, L&T, Kotak Mahindra, Gland Pharma and more
The stock market has witnessed a downward trend over the past few trading sessions. On Friday, January 17, the Indian benchmark equity indices broke their 3-day winning streak, closing in the red. The...
Gland Pharma gets EIR from US FDA for Pashamylaram facility after successful GMP inspection
Gland Pharma Limited announced the successful conclusion of the US FDA’s Good Manufacturing Practices (GMP) inspection at its Pashamylaram facility in Hyderabad. The inspection, which took place betwe...
Gland Pharma receives US FDA EIR for Dundigal facility after successful GMP inspection
Gland Pharma has received an Establishment Inspection Report (EIR) from the US FDA, confirming the successful closure of the Good Manufacturing Practices (GMP) inspection at its Dundigal facility in H...
Jefferies on CDMO players: Piramal Pharma top pick, upgrades Syngene, downgrades Gland Pharma
Jefferies highlights CY25 as a critical year for contract development and manufacturing organization (CDMO) players, with significant focus on earnings performance and market dynamics. Key Insights: E...
Gland Pharma shares rise nearly 2% following NSE’s inclusion in F&O contracts
Shares of Gland Pharma Ltd gained 1.62%, reaching ₹1,880.00, following the National Stock Exchange of India Ltd (NSE)’s announcement to include the stock in its futures and options (F&O) segment. This...